Is lincomycin (lincosin) a macrolide antibiotic?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Lincomycin (Lincosin) a Macrolide?

No, lincomycin (Lincosin) is not a macrolide—it is a lincosamide antibiotic that is structurally distinct from macrolides despite sharing similar mechanisms of action and resistance patterns. 1

Structural Classification

  • Lincomycin belongs to the lincosamide class of antibiotics, which is structurally different from macrolides 1
  • Macrolides are defined by a macrocyclic lactone ring of 12 or more elements (14-membered rings like erythromycin and clarithromycin, or 15-membered rings like azithromycin) 1
  • Lincosamides (lincomycin and clindamycin) have a completely different chemical structure that does not contain this characteristic lactone ring 2, 3

Shared Functional Properties (Why the Confusion Exists)

Despite being structurally distinct, lincosamides and macrolides share important functional similarities:

  • Both bind to the 50S ribosomal subunit to inhibit bacterial protein synthesis 1, 4
  • Specifically, lincomycin binds to the 23S RNA of the 50S subunit, similar to macrolides 4
  • Both are predominantly bacteriostatic but can be bactericidal at higher concentrations 2, 5
  • Cross-resistance exists between lincosamides and macrolides due to shared resistance mechanisms, particularly erm gene-mediated methylation of the 23S ribosomal RNA 1

Clinical Implications of the Distinction

  • Macrolide-resistant organisms should be tested for inducible resistance to lincosamides using the D-zone test, as resistance may be shared despite the structural differences 4
  • The British Thoracic Society notes that "such resistance may also be associated with resistance to lincosamides such as clindamycin" when discussing macrolide resistance mechanisms 1
  • This cross-resistance pattern (MLSB phenotype) means that if a pathogen is resistant to macrolides, it may also be resistant to lincosamides, even though they are different drug classes 4, 2

Common Pitfall

The most important clinical pitfall is assuming that because lincosamides and macrolides are structurally different, they won't have cross-resistance—in reality, organisms with erm-mediated macrolide resistance will often be resistant to lincosamides as well, requiring careful susceptibility testing before prescribing either class 1, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Lincosamides].

Pathologie-biologie, 1986

Research

Lincomycin, clindamycin and their applications.

Applied microbiology and biotechnology, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.